Prognostic Value of Osteopontin in Patients Treated with Primary Radiotherapy for Head and Neck Cancer

  • Etiz, Durmus (Department of Radiation Oncology, Eskisehir Osmangazi University Faculty of Medicine) ;
  • Ataizi, Fulya Colak (Department of Radiation Oncology, Eskisehir Osmangazi University Faculty of Medicine) ;
  • Bayman, Evrim (Department of Radiation Oncology, Eskisehir Osmangazi University Faculty of Medicine) ;
  • Akcay, Melek (Department of Radiation Oncology, Eskisehir Osmangazi University Faculty of Medicine) ;
  • Acikalin, Mustafa Fuat (Department of Pathology, Eskisehir Osmangazi University Faculty of Medicine) ;
  • Colak, Ertugrul (Department of Biostatistics, Eskisehir Osmangazi University Faculty of Medicine) ;
  • Ciftci, Evrim (Department of Pathology, Eskisehir Osmangazi University Faculty of Medicine)
  • 발행 : 2013.09.30


Background: The prognostic value of tumor osteopontin (OPN) in patients with squamous-cell head and neck cancer (SCHNC) was investigated. Materials and Methods: OPN expression was assessed by immunohistochemical methods in 50 patients, who were treated with primary radiotherapy (RT) for locally advanced SCHNC. The effects of OPN on clinical parameters, local-regional control after RT and metastasis-free survival, was assessed. Results: The rate of OPN expression in tumor tissue was 76%. OPN positive cases had lower Hb levels (p=0.088). Mean time to local recurrence was 53.8 months (SE 3.9) in OPN-negative cases and 39.1 months (SE 4.7) in OPN-positive cases (p=0.047). OPN increased the risk of local recurrence 5.9 times (p=0.085). It had no effect on metastasis-free (p=0.116) or overall survival (p=0.123). OPN was positive in 12 of 19 cases that developed grade 3-4 acute radiation dermatitis (p=0.096). Conclusions: OPN expression is associated with an increase in local recurrence in patients who were treated with primary RT for locally advanced SCHNC.


  1. Bache M, Reddemann R, Said HM, et al (2006). Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor- 1alpha-related markers, and hemoglobin levels. Int J Radiat Oncol Biol Phys, 66, 1481-7.
  2. Bramwell VH, Doig GS, Tuck AB, et al (2006). Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res, 12, 3337-43.
  3. Celetti A, Testa D, Staibano S, et al (2005). Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness. Clin Cancer Res, 11, 8019-27.
  4. Coppola D, Szabo M, Boulware D, et al (2004). Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res, 10, 184-90.
  5. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS (2001). Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest, 107, 1055-61.
  6. Denhardt DT, Mistretta D, Chambers AF, et al (2003). Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin Exp Metastasis, 20, 77-84.
  7. Devoll RE, Li W, Woods KV, et al (1999). Osteopontin (OPN) distribution in premalignant and malignant lesions of oral epithelium and expression in cell lines derived from squamous cell carcinoma of the oral cavity. J Oral Pathol Med, 28, 97-101.
  8. Giachelli CM, Steitz S (2000). Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol, 19, 615-22.
  9. Le QT, Kong C, Lavori PW, et al (2007). Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys, 69,167-75.
  10. Hoogsteen IJ, Marres HA, Bussink J, van der Kogel AJ, Kaanders JH (2007). Tumor microenvironment in head and neck squamous cell carcinomas: predictive value and clinical relevance of hypoxic markers. A review. Head Neck, 29, 591-604.
  11. Huan JL, Xing L, Qin XJ, et al (2012). Expression and clinical significance of osteopontin in calcified breast tissue. Asian Pac J Cancer Prev, 13, 5219-23.
  12. Le QT, Sutphin PD, Raychaudhuri S, et al (2003). Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res, 9, 59-67.
  13. Leo C, Giaccia AJ, Denko NC (2004). The hypoxic tumor microenvironment and gene expression. Semin Radiat Oncol, 14, 207-14.
  14. Lim AM, Rischin D, Fisher R, et al (2012). Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial. Clin Cancer Res, 18, 301-7.
  15. Lu JG, Li Y, Li L, Kan X (2011). Overexpression of osteopontin and integrin $\alpha{v}$ in laryngeal and hypopharyngeal carcinomas associated with differentiation and metastasis. J Cancer Res Clin Oncol, 137, 1613-8.
  16. Nordsmark M, Bentzen SM, Rudat V, et al (2005). Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol, 77, 18-24.
  17. Snitcovsky I, Leitao GM, Pasini FS, et al (2009). Plasma osteopontin levels in patients with head and neck cancer undergoing chemoradiotherapy. Arch Otolaryngol Head Neck Surg, 135, 807-11.
  18. Overgaard J, Eriksen JG, Nordsmark M, et al (2005). Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomized double-blind placebocontrolled trial. Lancet Oncol, 6, 757-64.
  19. Rischin D, Hicks RJ, Fisher R et al (2006). Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol, 24, 2098-104.
  20. Seier AM, Renkl AC, Schulz G, et al (2010). Antigen-specific induction of osteopontin contributes to the chronification of allergic contact dermatitis. Am J Pathol, 176, 246-58.
  21. Sorensen BS, Hao J, Overgaard J, et al (2005). Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother Oncol, 76, 187-93.
  22. Toustrup K, Sorensen BS, Alsner J, Overgaard J (2012). Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. Semin Radiat Oncol, 22, 119-27.
  23. Tuck AB, Arsenault DM, O'Malley FP, et al (1999). Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene, 18, 4237-46.
  24. Vaupel P, Hockel M (1998). Oxygenation of human tumors. In: Molls M, Vaupel P (Eds): Medical radiology: blood perfusion and microenvironment of human tumors. pp 63-72.
  25. Vergis R, Corbishley CM, Norman AR, et al (2008). Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomized radiotherapy trials an done surgical cohort study. Lancet Oncol, 9, 342-51.
  26. Wu CY, Wu MS, Chiang EP, et al (2007). Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut, 56, 782-9.
  27. Yaromina A, Krause M, Baumann M (2012). Individualization of cancer treatment from radiotherapy perspective. Mol Oncol, 6, 211-21.

피인용 문헌

  1. The prognostic value of osteopontin expression in non-small cell lung cancer: a meta-analysis vol.45, pp.5, 2014,
  2. Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival vol.7, pp.1, 2015,
  3. Human osteopontin: Potential clinical applications in cancer (Review) vol.39, pp.6, 2017,